QT studies are required for drug approval but are expensive and inappropriately scheduled. A better repolarization assessment can be achieved earlier and at lower cost and risk to subjects as compared to the ICH E-14 thorough QT study approach. This session will review efforts now underway to revise the process for assessing repolarization and related arrhythmia risk during drug development.